CASI Pharma (CASI) Misses Q3 EPS by 2c

CASI Pharma (NASDAQ: CASI) reported Q3 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.1 million versus the consensus estimate of $7.54 million.

For earnings history and earnings-related data on CASI Pharma (CASI) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
• Marpai, Inc. (MRAI) Misses Q2 EPS by 18c